X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AT-527 (bemnifosbuvir) is a nucleotide polymerase inhibitor, targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and vRuzasvir (RZR), an oral NS5A inhibitor for Treatment of Hepatitis C.
Lead Product(s): Bemnifosbuvir,Ruzasvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-527
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
Under the terms of the agreement, Atea will develop, manufacture and commercialize AT-038 (ruzasvir), an oral NS5A inhibitor, in combination with AT-527 (bemnifosbuvir) as a pan-genotypic regimen for the treatment of hepatitis C (HCV).
Lead Product(s): Ruzasvir,Bemnifosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-038
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Atea Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
